Malignant Hepatobiliary Neoplasm — Trials

Malignant Hepatobiliary Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

5,025 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,159
Recruiting: 665
Ph III recruiting: 61
Growth YoY: +9%
Industry share: 22%
Top sponsor: Sun Yat-sen University
Termination share: 32.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (560)

clinicaltrialsPublishedShowing 401–450 of 591 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02346032	Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma	completed	Phase 2	4	Samsung Medical CenterOTHER	0	Apr 26, 2017	clinicaltrials
NCT01007552	A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts	completed	Phase 2	50	Roswell Park Cancer InstituteOTHER	1	Mar 29, 2017	clinicaltrials